SCHEDULE: Invus Group Discloses 5.3% Stake in Tango Therapeutics
Beneficial Ownership Disclosure
Raymond Debbane and affiliated entities, collectively known as The Invus Group, have disclosed a 5.3% beneficial ownership stake in Tango Therapeutics, Inc.
Summary
- Raymond Debbane and associated entities, including Invus Public Equities, L.P. and Avicenna Life Sci Master Fund LP, collectively hold 5,883,188 shares of Tango Therapeutics, Inc. common stock.
- This aggregate holding represents a 5.3% beneficial ownership of Tango Therapeutics' outstanding common stock.
- The percentage of ownership is calculated based on 111,260,247 shares outstanding as of July 29, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on August 5, 2025.
- The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing the control of Tango Therapeutics, Inc.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of beneficial ownership, indicating a significant stake by an institutional investor group. It does not contain performance-related information to assess positive or negative sentiment regarding the company's operations or financial health.
Positives
- A significant institutional investor group, led by Raymond Debbane, has taken a notable stake in Tango Therapeutics, potentially signaling confidence in the company's long-term prospects.
Negatives
- No specific negative information regarding Tango Therapeutics, Inc. is disclosed in this ownership filing.
Risks
- No specific risks related to Tango Therapeutics, Inc. are detailed in this ownership disclosure.
Future Outlook
This filing, a Schedule 13G, is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Tango Therapeutics, Inc.
Management Comments
- No notable quotes or paraphrased statements from Tango Therapeutics' management are included in this ownership filing.
Industry Context
This Schedule 13G filing primarily concerns beneficial ownership disclosure and does not provide specific analysis of broader industry trends or competitor comparisons for Tango Therapeutics, Inc.
Comparison to Industry Standards
- No specific comparison to industry benchmarks, comparable companies, projects, or results is provided in this beneficial ownership filing.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- No litigation or regulatory matters concerning Tango Therapeutics, Inc. are disclosed in this filing.
Related Party Transactions
- No related party transactions involving Tango Therapeutics, Inc. are disclosed in this filing.
Stakeholder Impact
- Shareholders: Disclosure of a significant institutional stake by The Invus Group, led by Raymond Debbane, may influence market perception and investor confidence.
Next Steps
- This filing does not outline any specific future actions, events, or milestones for Tango Therapeutics, Inc.
Key Dates
| Date | Description |
|---|---|
| 07/29/2025 | Date of shares outstanding calculation for Tango Therapeutics, Inc. |
| 08/05/2025 | Date Tango Therapeutics, Inc. filed its Quarterly Report on Form 10-Q, reporting shares outstanding. |
| 09/19/2025 | Date of the event which required the filing of this statement. |
| 09/22/2025 | Date of signing of the Schedule 13G and Joint Filing Agreement by the reporting persons. |
Keywords
Tango Therapeutics, TNGX, Invus, Raymond Debbane, institutional ownership, Schedule 13G, beneficial ownership, common stock, biotech, pharmaceutical
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.